Today's Peptide News — September 5, 2026

Researchers report a computational, de novo strategy for designing short α-helical peptides that spontaneously self-assemble into large, stable, membrane-spanning nanopores with potent antimicrobial activity, including in vivo efficacy against drug-resistant pathogens. Rather than screening natural sequences by trial and error, the team combined large-scale molecular simulations with multiscale validation and targeted experiments to establish general design rules linking a peptide's sequence to the architecture, stability, and transport properties of the pore it forms. The most potent designs reached minimum inhibitory concentrations of roughly 0.4 to 0.8 micromolar, substantially below ampicillin.

Because pore geometry and biological activity can now be tuned rationally, the approach turns antimicrobial peptide discovery into something closer to engineering. The authors note the same modular, programmable scaffolds could serve beyond infection control as biosensors and as responsive drug-delivery systems.

This is the strongest PeptideWiki candidate of the day. A good short post would explain how a designed peptide "drills" a self-assembling hole through a bacterial membrane, and why programmable pore design matters for the antibiotic-resistance crisis. It pairs naturally with an existing entry on natural pore-forming antimicrobial peptides for contrast.

A new review surveys peptide-based therapeutics for Alzheimer's disease, focusing on three linked problems: designing peptides that hit the right target, using AI-guided computational methods to optimize them, and getting them across the blood-brain barrier. Peptides are attractive here because they can modulate the protein-protein interactions that drive amyloid-β aggregation and tau hyperphosphorylation, interactions that small molecules struggle to reach, while offering favorable specificity and safety profiles. The review highlights "shuttle" peptides engineered specifically to carry therapeutic cargo past the barrier that has defeated many Alzheimer's candidates.

Delivery, not target engagement, has long been the bottleneck for central nervous system peptide drugs, so a synthesis that treats blood-brain barrier transit as a design parameter is timely as more programs move toward the clinic.

For PeptideWiki, this supports a primer on blood-brain-barrier shuttle peptides: what they are, how a transport peptide is fused to a therapeutic payload, and why the strategy could unlock a class of neuro-targeted peptide drugs. It also refreshes any existing amyloid-β or tau entries with a delivery-focused angle.

A collected body of work outlines the next generation of peptide therapeutics for obesity moving beyond single-target GLP-1 agonists toward multi-receptor designs that engage GLP-1, GIP, glucagon, and amylin pathways in one molecule. These unimolecular agonists aim for deeper weight loss and broader cardiometabolic benefit than first-generation drugs, while raising fresh questions about muscle preservation, tolerability, and long-term safety as potency climbs.

The framing matters because the obesity field is shifting from "does a GLP-1 drug work" to "which combination of hormone signals gives the best benefit-to-risk balance," and peptides remain the dominant chemistry for hitting several receptors at once.

A PeptideWiki post could use this as a map of the multi-agonist landscape, briefly defining each hormone axis (GLP-1, GIP, glucagon, amylin) and pointing to the specific drugs, retatrutide, cagrilintide combinations, and amycretin, that occupy each niche. It works well as a hub entry linking out to individual drug pages.

Eli Lilly announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials of retatrutide, its triple agonist targeting the GIP, GLP-1, and glucagon receptors. Participants on the 4 mg, 9 mg, and 12 mg doses lost an average of about 12.7%, 19.1%, and 20.8% of body weight respectively, alongside A1C reductions of up to 1.6%. The results extend a run of five positive Phase 3 readouts, with six more late-stage TRIUMPH studies expected to report by the end of 2026.

Retatrutide has produced some of the largest weight reductions yet seen for an obesity drug, positioning it as a potential step beyond Lilly's own tirzepatide. A regulatory filing is expected in late 2026, with approval unlikely before 2027 or 2028. Earlier reporting has also flagged a safety signal to watch as the dataset matures, a reminder that greater potency invites closer scrutiny.

Orforglipron, a once-daily oral GLP-1 receptor agonist, continues to build its case as the first convenient pill in a field dominated by injectables. Lilly reported that the drug bested semaglutide on A1C reduction in a head-to-head type 2 diabetes trial and outperformed a standard oral diabetes drug in a separate Phase 3 study, following positive results from its ATTAIN maintenance program. The candidate has been filed with the FDA, with a decision expected in 2026.

Because orforglipron is a small molecule rather than a peptide, it can be manufactured and distributed far more cheaply than injectable peptide GLP-1 drugs, which could widen access considerably if approved. Its progress is a useful contrast point for PeptideWiki: it shows where the incretin field is deliberately moving away from peptide chemistry, and why.

The obesity pipeline's next competitive front is amylin. Novo Nordisk's zenagamtide (amycretin), a unimolecular GLP-1/amylin agonist, advanced to Phase 3 after roughly 22% weight loss in earlier data, while Novo's CagriSema, pairing the amylin analog cagrilintide with semaglutide, nears an FDA decision guided toward late 2026. Viking Therapeutics' dual GLP-1/GIP agonist VK2735 has fully enrolled both pivotal trials of its VANQUISH program, with readouts expected in 2027.

Amylin-based combinations are emerging as the leading strategy to push past the roughly 15-20% weight loss ceiling of current drugs while improving tolerability. For PeptideWiki, this is fresh material for entries on cagrilintide and amylin-class peptides, and a chance to explain why layering an amylin signal onto a GLP-1 backbone is the field's hottest design idea.

A once-nightly oral drug reduced breathing interruptions by roughly 44% in a major Phase 3 obstructive sleep apnea trial, according to newly reported results. If confirmed and approved, it would offer a pharmacological option for a condition still managed largely with CPAP machines that many patients struggle to tolerate. The finding adds to a broader 2026 theme of metabolic and respiratory conditions becoming targets for daily oral therapies.

New research suggests obesity leaves a lasting molecular mark on key immune cells, an imprint that may persist for five to ten years even after significant weight loss. The finding helps explain why some obesity-related health risks do not fully reverse when weight comes off, and points to the immune system as a durable record of past metabolic state. It raises the question of whether future therapies will need to address this immune memory directly rather than relying on weight reduction alone.

Scientists have developed nanoparticles that serve two roles in glioblastoma surgery: they make otherwise invisible tumor cells glow during an operation so surgeons can see the margins, then destroy the microscopic disease left behind afterward. Glioblastoma is notoriously difficult to fully resect because its cells infiltrate healthy brain tissue, and residual cells drive its near-universal recurrence. A tool that both illuminates and treats those cells could improve one of oncology's most stubborn outcomes.

A giant iceberg measuring more than 76 square kilometers broke away from Greenland's Petermann Glacier in August 2026, marking the Arctic's largest glacier calving event since 2020. Calvings of this scale draw attention because the Petermann Glacier helps buttress inland ice, and losing large sections of its floating tongue can accelerate ice flow toward the sea. The event is a visible marker of the continued strain on Greenland's ice under a warming climate.